Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders (Tables)

9 Months Ended

Sep. 30, 2021

Earnings Per Share [Abstract]

Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders

The following table sets forth the computation of the basic and diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders for the three and nine months ended September 30, 2021 and 2020, respectively (in thousands, except share and per share amounts):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2021			2020			2021			2020
Net loss attributable to Adaptive Biotechnologies Corporation	$	(55,903	)	$	(36,719	)	$	(145,846	)	$	(101,657	)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted		140,833,564			134,372,026			140,060,379			129,289,948
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted	$	(0.40	)	$	(0.27	)	$	(1.04	)	$	(0.79	)

Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share

The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders for the three and nine months ended September 30, 2021 and 2020, respectively, as they had an anti-dilutive effect:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
Stock options issued and outstanding		12,901,028		15,718,821		13,205,328		16,484,334
Nonvested restricted stock units		795,469		50,000		572,194		34,138
Common stock warrant		—		56,875		11,458		56,875
Total		13,696,497		15,825,696		13,788,980		16,575,347